This study provides an experimental assessment of model-guided AMP discovery and a reproducible route from computational prediction to validated antimicrobial candidates, while revealing biases and generalizability limits of AI-based AMP inference.
Abstract
The emergence of antibiotic-resistant pathogens such as Staphylococcus aureus demands accelerated antimicrobial discovery strategies. Artificial intelligence (AI) enables large-scale inference of candidate antimicrobial peptides (AMPs), yet experimental validation remains essential to determine whether predictions translate into biological function. Genome-guided mining, rather than unconstrained or randomly generated sequence exploration, offers a biologically grounded search space derived from organisms shaped by ecological and evolutionary pressures. Here, we evaluate this principle using Malassezia furfur, a skin-associated yeast that coexists with bacterial colonizers such as S. aureus, as a genomic source for AI-prioritized antimicrobial candidates. Candidate fragments were generated from two M. furfur genomes, filtered by physicochemical properties, prioritized with deep-learning AMP predictors, synthesized, and experimentally characterized. Selected peptides underwent cross-kingdom antimicrobial screening against S. aureus, combining kinetic growth and ultrastructural assays, complemented by in silico structural prediction, lipid-membrane interaction analysis, and human keratinocyte cytotoxicity evaluation. AI-guided genomic mining enriched biologically motivated sequence space for peptides with measurable antimicrobial activity, while revealing biases and generalizability limits of AI-based AMP inference. Closing the loop between genome-derived candidate generation, AI-based inference, synthesis, and functional characterization, this study provides an experimental assessment of model-guided AMP discovery and a reproducible route from computational prediction to validated antimicrobial candidates.
The findings highlighted a promising application of deep evolutionary machine learning techniques for screening a range of novel AMPs for selective antimicrobial agents.
The rise and extent of antimicrobial resistance demand computational tools that go beyond simple predictions of antimicrobial activity to deliver applicable medicinal chemistry insights for an accelerated and more efficient development of novel antimicrobials. Here, we present a fragment-based explainable artificial...
Abdulmujeeb T. Onawole, M. Blaskovich, Johannes Zuegg· ACS Infectious Diseases· 0 citations
A sequence-traceable workflow linking proteome-scale eAMP discovery with structural prioritisation and experimental activity assessment is established, establishing a sequence-traceable workflow linking proteome-scale eAMP discovery with structural prioritisation and experimental activity assessment.
The utility of deep learning for prioritizing novel AMP candidates while highlighting the importance of experimental validation is demonstrated and the identified candidates provide a valuable resource for future functional studies and the development of peptide-based antimicrobial therapeutics.
Fabiano Pinheiro da Silva, S. Ariga, Thaís Martins de Lima et al.· Journal of Parasitology· 0 citations
A snapshot of AI-driven technologies for AMP design is provided and two modes of AI-driven technologies for AMP design are surveyed, one concentrated on identifying whether current data possess antimicrobial activity and the other on generating AMP candidates with potential therapeutic properties (generation-oriented).
Yong-Qiang Liu, Jie Hu, Ning Zhang et al.· Synthetic and Systems Biotec...· 0 citations
Experimental results demonstrate that PPsAMP significantly outperforms state-of-the-art models for identifying sAMPs, and has identified 14,839 candidate sAMPs from environmental metagenomes, most of which have not been previously reported.
Sheng-Xi Liu, Xi-Zhe Gao, Jing-Yu Wang et al.· Journal of Chemical Informat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.